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HLA-Independent Antibacterial Host 
Response toward Th1 Immunity 
Mediated by IL-12: a New Concept for 
the Pathogenesis of Adamantiades–
Behçet’s Disease
Christos C. Zouboulis1,2
Yanagihori et al. found an HLA-independent higher frequency of IL-12B promot-
er polymorphism in Adamantiades–Behçet’s disease (ABD) patients than in con-
trols. Stimulation with streptococcal antigens specifically increased expression 
of patients’ peripheral blood mononuclear cells IL-12 p40/p70. The authors pro-
vide evidence for an antibacterial host response toward T-helper type 1 immunity 
mediated by IL-12 in patients with ABD, which is HLA independent.
Journal of Investigative Dermatology (2006) 126, 1444–1447. doi:10.1038/sj.jid.5700281
Adamantiades–Behçet’s disease (ABD) is 
a multisystemic, inflammatory disorder 
of unknown etiology with hyperergic 
behavior and a chronic recurrent course 
(Sakane et al., 1999). It is characterized 
by oral and genital ulcerations, various 
cutaneous manifestations, and ocular 
involvement, whereas mucocutaneous 
lesions exhibit histological changes of 
vascular reaction or vasculitis. Linked 
intrinsic and extrinsic factors are con-
sidered to contribute to the develop-
ment of the disease, and this has led to 
the concept of environmental triggering 
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for increased production of murine 
S100A15 mRNA and protein appears 
to require protein kinase C activity, 
as the calcium-dependent increase in 
murine S100A15 level is inhibited by 
protein kinase C inhibitors. Activator 
protein-1 transcription factors appear 
to be a downstream target that medi-
ates the protein kinase C-dependent 
increase in murine S100A15, as the 
presence of a dominant-negative vari-
ant of c-Jun inhibits the increase in 
murine S100A15.
It is gratifying to have confirmation 
that S100A7 expression, regulation, 
and subcellular localization are simi-
lar in human and murine epidermis. 
Moreover, it is clear that the availabil-
ity of the S100A15 sequence will pro-
vide an important new tool to identify 
the role of S100A7 and S100A15 in 
normal epidermal development and in 
cutaneous diseases and cancer.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work used the facilities of the Skin Diseases 
Research Center of Northeast Ohio (National 
Institutes of Health grant AR39750) and was 
supported by a grant from the National Institutes 
of Health (to R.L.E.).
REFERENCES
Broome AM, Ryan D, Eckert RL (2003) S100 
protein subcellular localization during 
epidermal differentiation and psoriasis. J 
Histochem Cytochem 51:675–85
Donato R (2001) S100: a multigenic family of 
calcium-modulated proteins of the EF-hand 
type with intracellular and extracellular 
functional roles. Int J Biochem Cell Biol 
33:637–68
Eckert RL, Broome AM, Ruse M, Robinson N, 
Ryan D, Lee K (2004) S100 proteins in the 
epidermis. J Invest Dermatol 123:23–33
Glaser R, Harder J, Lange H, Bartels J, 
Christophers E, Schroder JM (2005) 
Antimicrobial psoriasin (S100A7) protects 
human skin from Escherichia coli infection. 
Nat Immunol 6:57–64
Hagens G, Masouye I, Augsburger E, Hotz R, 
Saurat JH, Siegenthaler G (1999a) Calcium-
binding protein S100A7 and epidermal-type 
fatty acid-binding protein are associated in 
the cytosol of human keratinocytes. Biochem 
J 339:419–27
Hagens G, Roulin K, Hotz R, Saurat JH, Hellman 
U, Siegenthaler G (1999b) Probable 
interaction between S100A7 and E-FABP 
in the cytosol of human keratinocytes from 
psoriatic scales. Mol Cell Biochem 192:123–8
Heizmann CW, Fritz G, Schafer BW (2002) S100 
proteins: structure, functions and pathology. 
Front Biosci 7:d1356–68
Jinquan T, Vorum H, Larsen CG, Madsen P, 
Rasmussen HH, Gesser B et al. (1996) 
Psoriasin: a novel chemotactic protein. J 
Invest Dermatol 107:5–10
Madsen P, Rasmussen HH, Leffers H, Honore 
B, Celis JE (1992) Molecular cloning and 
expression of a novel keratinocyte protein 
(psoriasis-associated fatty acid-binding 
protein [PA-FABP]) that is highly up-regulated 
in psoriatic skin and that shares similarity to 
fatty acid-binding proteins. J Invest Dermatol 
99:299–305
Madsen P, Rasmussen HH, Leffers H, Honore B, 
Dejgaard K, Olsen E et al. (1991) Molecular 
cloning, occurrence, and expression of a 
novel partially secreted protein “psoriasin” 
that is highly up-regulated in psoriatic skin. J 
Invest Dermatol 97:701–12
Ridinger K, Ilg EC, Niggli FK, Heizmann CW, 
Schafer BW (1998) Clustered organization of 
S100 genes in human and mouse. Biochim 
Biophys Acta 1448:254–63
Ruse M, Broome AM, Eckert RL (2003) S100A7 
(psoriasin) interacts with epidermal fatty 
acid binding protein and localizes in 
focal adhesion-like structures in cultured 
keratinocytes. J Invest Dermatol 121:132–41
Wolf R, Mirmohammadsadegh A, Walz M, Lysa 
B, Tartler U, Remus R et al. (2003) Molecular 
cloning and characterization of alternatively 
spliced mRNA isoforms from psoriatic skin 
encoding a novel member of the S100 family. 
FASEB J 17:1969–71
Wolf R, Voscopoulos CJ, FitzGerald PC, 
Goldsmith P, Cataisson C, Gunsior M et al. 
(2006) The mouse S100A15 ortholog parallels 
genomic organization, structure, gene 
expression, and protein-processing pattern 
of the human S100A7/A15 subfamily during 
epidermal maturation. J Invest Dermatol 
126:1600–08 
COMMENTARY
 www.jidonline.org 1445
of a genetically determined disorder 
(Zouboulis and May, 2003). Genetic fac-
tors have been investigated, and a link 
with several HLA alleles had initially 
been suggested. The confirmed associa-
tion with HLA-B51, especially with HLA-
B5101, represents a prognostic marker 
rather than a genetic factor (Zouboulis 
et al., 2003a). Recently, a possible role 
of MICA of the major histocompatibility 
complex region has been emphasized.
At least four extrinsic pathoge-
netic candidates have been identified 
(Lehner, 1999), including autoimmu-
nity or crossreactivity between micro-
bial and oral mucosal antigens, human 
simplex virus infection affecting the 
immune responses, and certain bacteria 
(Streptococcus sanguinis, Mycoplasma 
fermentans) (Zouboulis and May, 2003). 
A bacterial etiology was suggested in 
1931 by Adamantiades. The Behçet’s 
Disease Research Committee of Japan 
reported systemic ABD signs in patients 
within 1–2 weeks after controlled con-
tact with several Streptococcus strains, 
Escherichia coli, and Klebsiella pneu-
moniae. S. sanguinis dominates the flora 
of the oral mucosa in ABD patients and 
appears to be the most relevant bac-
terium, at least in Japanese patients, as 
a provoking factor for the initiation of 
the disease. Streptococcal antigens and 
anti-streptococcal antibodies are fre-
quently found in the oral mucosa and 
serum of ABD patients. The BeS-1 gene 
encoding the immunogenic antigen 
of S. sanguinis KTH-1, a 95-kilodalton 
antigen isolated from the patients with 
ABD, has been cloned and sequenced. 
A BeS-1 DNA fragment was detected in 
erythema nodosum-like eruption and 
oral aphthous lesions in ABD (Tojo et 
al., 2003). The involvement of IgA pro-
tease-producing S. sanguinis species was 
proposed as an explanation for a chroni-
fication of the infection. On the other 
hand, mycoplasmas cause infections 
of mucosal tissue, colonizing epithelia 
of the respiratory or genital tract, and 
M. fermentans especially has been 
associated with rheumatic diseases. 
Moreover, mycoplasmas are known 
to exhibit molecular mimicry with 
eukaryotic structures that may modu-
late immune responses. Most myco-
plasmas contain macrophage-activating 
components, and macrophages have 
been shown to be strongly stimulated 
by a factor(s) circulating in the serum 
of ABD patients (Alpsoy et al., 2003). 
MALP-404, the M. fermentans lipopro-
tein, which has been detected in serum 
of ABD patients, contains the peptide 
motif -G------F, which can be presented 
by HLA-B51 (Zouboulis et al., 2003b).
However, ABD is not considered to be 
contagious, as no horizontal transmis-
sion has ever been reported. Common 
factors linking some of the possible 
pathogenetic agents are microbial stress 
and heat shock proteins (HSPs), which 
crossreact with host tissues and elicit 
significant T-cell responses (Direskeneli 
and Saruhan-Direskeneli, 2003). T-cell 
epitope mapping has identified four 
peptides derived from the sequence of 
a 65-kilodalton bacterial HSP, which 
stimulate proliferation of γδ+ TCR 
lymphocytes of patients with ABD. 
These peptides show significant homol-
ogy with the corresponding peptides 
derived from the human 60-kilodalton 
mitochondrial HSP. In the cerebro spinal 
fluid of patients with parenchymal 
neurological involvement, an increased 
level of anti-HSP antibodies could be 
found. On the other hand, IgA isotype 
of antibodies specific for mycobacterial 
tuberculosis HSP-65 could crossreact 
with certain serotypes of S. sanguinis. 
In general, crossreactions between 
microbial and human HSP possibly 
link infection with autoimmunity. The 
upregulation of T cells observed in ABD 
patients suggests that the etiological 
agents may include 65-kilodalton HSP 
peptides shared between common bac-
teria, superantigens such as bacterial 
toxins, or viruses and human tissues. 
Interestingly, the MICA protein is recog-
nized by T lymphocytes with a variable 
Vγδ region in their TCR, and antigens 
presented to γδ+CD8+ T cells are assisted 
by the MICA molecule.
The endothelium seems to be the 
primary target in this disease; however, 
it may simply be subject to the com-
plex and as-yet unexplained behavior 
of the immune system (Kalayciyan and 
Zouboulis, 2006). The diverse existing 
data may be interpreted in favor of either 
possibility. Lee et al. (2003) have iden-
tified an IgM-type anti-endothelial cell 
surface antibody in the serum of ABD 
patients and identified the antigen as 
endothelial α-enolase, a 47-kilodalton 
HSP. On the other hand, α-enolase is 
an abundant enzyme in the glycolytic 
pathway, and streptococcal α-enolase 
is a cell-surface plasminogen-binding 
protein. The finding that plasmin bound 
to streptococcal α-enolase retains its 
proteolytic activity even in the presence 
of α2-antiplasmin indicates that strepto-
coccal α-enolase may be an important 
streptococcal virulence determinant. 
α-enolase is also found in mycoplas-
mas, especially in significant amounts in 
M. fermentans. α-enolase may play a 
role in endothelial-cell injury, either 
through its expression on the endo-
thelial-cell surface, resulting in auto-
antibody and local immune complex 
formation, or through the association 
of plasminogen/plasmin and bacterial 
enolase, causing direct damage to extra-
cellular matrix, possibly by enzymatic 
degradation of matrix proteins or other 
protein constituents. However, the spec-
ificity of autoantibodies directed against 
α-enolase in ABD is unclear. They have 
previously been described in some 
chronic inflammatory diseases, such as 
rheumatoid arthritis, systemic lupus 
erythematosus, systemic sclerosis, and 
inflammatory bowel disease (Kalayciyan 
and Zouboulis, 2006). Inceased anti-
enolase antibody levels may represent 
endothelial injury or even vasculitis rath-
er than being specific for a particular dis-
ease. Moreover, these antibodies seem to 
bind to different isoforms of α-enolase in 
different diseases. Interestingly, the pres-
ence and the titer of anti-endothelial cell 
antibodies have been correlated with 
disease activity in systemic vasculitis. 
Rather than being cytotoxic to endothe-
lial cells, anti-endothelial cell antibodies 
are able to upregulate the expression of 
adhesion molecules and to induce the 
secretion of cytokines and chemokines 
that, in turn, cause leukocyte recruit-
ment and adhesion (Zouboulis and 
May, 2003). Moreover, both hemostatic 
|
The 4 bp insertion 
polymorphism within 
the IL-12B promoter 
region contributes to 
susceptibility to ABD.
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and fibrinolytic pathway markers were 
found activated in the presence of anti-
endothelial cell antibodies, suggesting 
an altered endothelial cell surface acti-
vation state. The significance of the fact 
that the α-chain of enolase is completely 
homologous with the enhancer of IgM 
production Ig production-stimulating 
factor-2β is yet unknown.
These findings propose that α-eno-
lase may modify the function of the 
cell wall. After uptake of HSP-peptide 
complexes by antigen-presenting cells 
and “cross-presentation” of HSP-chap-
eroned peptides on major histocom-
patibility complex class I molecules, a 
CD8-specific T-cell response is induced. 
HSPs per se provide activation signals 
for the innate immune system. Binding 
of peptide-free HSP-70 to antigen-pre-
senting cells via Toll-like receptors may 
initiate the secretion of proinflamma-
tory cytokines and thus result in a broad 
nonspecific immunostimulation.
Various proinflammatory cytokines, 
such as IL-1, IL-8, and tumor necro-
sis factor-α, are elevated in the sera 
of ABD patients. IL-8 seems to play 
an especially important role, as it can 
also be released by endothelial cells 
and is a sensitive marker of the disease 
activity (Zouboulis and May, 2003). 
Therefore, neutrophils may also be 
involved in the pathogenesis of ABD, as 
they are attracted by macrophage- and 
endothelial cell-released cytokines and 
chemokines at the site of the lesions, 
especially by IL-8, and thus contribute 
to tissue damage and self-maintenance 
of inflammation. The chronic local 
inflammation process together with 
platelet and serum factors can lead to 
enhanced coagulation and thrombosis.
IL-12 has recently drawn attention 
in ABD through correlation of its serum 
levels with disease activity, suggested 
to represent a pathogenetic role of a 
T-helper type 1 (Th1) immune response 
in ABD (Frassanito et al., 1999). IL-12 
is mainly produced by antigen-present-
ing cells and plays a crucial role in the 
obligatory transformation of naive T cells 
into Th1 cells (Trinchieri, 1993; Alber et 
al., 2006). IL-12 is generated in ABD by 
stimulation of CD4+ T lymphocytes with 
HSP-336–351 and can also be secreted 
by neutrophils. Innate immune recogni-
tion of bacteria was recently shown to 
involve Toll-like receptor-2 expressed on 
immature dendritic cells and Vδ2 T lym-
phocytes expressing γδ+ TCR. Activated 
Vδ2 T cells enhance Toll-like receptor-
2-induced dendritic-cell maturation, 
which costimulates IL-12 p70 secretion 
by dendritic cells (Shrestha et al., 2005). 
γδ+ T lymphocytes were shown to pro-
liferate in the presence of IL-12 (Brown 
et al., 1996). On the other hand, HSP-
60 is regarded as an endogenous “dan-
ger” signal to the immune system with 
rapid inflammatory cytokine release 
and the enhancement of adaptive Th1 
responses (Direskeneli and Saruhan-
Direskeneli, 2003).
Yanagihori et al. (2006, this issue) 
elucidated a characteristic gene poly-
morphism of IL-12 in ABD in order to 
approach its relevance to the immun-
opathogenesis of the disease. On the 
other hand, the authors provide addi-
tional evidence that HLA genes are not 
associated with ABD (Zouboulis et al., 
2003a). IL-12 is composed of two het-
erodimeric subunits, a 35-kilodalton 
chain encoded by p35 and a 40-kilodal-
ton chain encoded by p40 (IL-12B). The 
authors investigated IL-12B promoter 
polymorphism, for which the 4 bp het-
erozygous insertion has been shown to 
affect the gene transcription and subse-
quent protein production, by analyzing 
IL-12B promoter genotypes in a large 
cohort of 92 Japanese ABD patients and 
102 normal control subjects with the use 
of PCR-based restriction enzyme diges-
tion. They found that the frequency of 
the insertion heterozygosity was signifi-
cantly higher in patients (53.3%) than in 
control subjects (38.2%), showing that 
the 4 bp insertion polymorphism within 
the IL-12B promoter region contributes 
to susceptibility to ABD. More specifical-
ly, this allelic variation is closely associ-
ated with increased production of IL-12 
p40 mRNA and protein, in conjunction 
with IL-12 p70 induction in peripheral 
blood mononuclear cells from hetero-
zygous ABD patients in response to the 
common bacterial antigens, as assessed 
by semiquantitative reverse transcrip-
tion PCR and ELISA. The most pro-
nounced reaction was obtained in the 
patients’ peripheral blood mononuclear 
cells upon stimulation with KTH-1 S. 
sanguinis antigen. These results indicate 
the involvement of a differential immune 
response against environmental micro-
organisms in ABD and provide evidence 
for an extrinsically pathogenic relevance 
of streptococcal antigens mediated by 
IL-12 in ABD and for antibacterial host 
response toward Th1 immunity. It is like-
ly that IL-12B promoter heterozygosity 
contributes not only to ABD susceptibil-
ity, at least in Japanese patients, but also 
to loss of feedback inhibition of IL-12 
p40 gene expression.
In addition, Yanagihori et al. (2006) 
compared the frequency of the inser-
tion heterozygosity of the IL-12B pro-
moter with HLA haplotype data in their 
patients and confirmed that the possible 
genetic susceptibility is independent of 
HLA background. Thus, identification of 
new ABD susceptibility genes relevant to 
abnormal immunobiological response 
against bacterial antigens still remains 
an important challenge.
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A New Wrinkle on Topical Vitamin E 
and Photo-inflammation: Mechanistic 
Studies of a Hydrophilic γ-Tocopherol 
Derivative Compared with 
α-Tocopherol
Raymond L. Konger1,2
The antioxidant function of vitamin E is thought to mediate its photo-protec-
tive effects. Cyclooxygenase-2 (COX-2) is an important mediator of early 
photo-inflammation. Thus, the ability of γ-tocopherol to inhibit COX-2 activity 
independently of its antioxidant function raises important questions regarding 
potential roles that this form of vitamin E plays in photo-protection and skin 
cancer chemoprevention.
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Since Linus Pauling published his 
widely read and publicly debated trea-
tise Vitamin C and the Common Cold 
in 1970, there has been tremendous 
lay interest in the potential protective 
effects of antioxidants in a variety of ail-
ments. This interest did not escape the 
cosmetic industry. Currently, pharmacy 
shelves are well stocked with skin-care 
products, sunblocks, and sun-tanning 
lotions that tout the remarkable anti-
oxidant properties of vitamin E. Given 
that there is good evidence that vita-
min E may have protective functions 
within the epidermis, this widespread 
use cannot be simply trivialized as a 
long-term marketing ploy. However, 
there is no good consensus regarding 
the clinical utility of the various natu-
rally occurring forms of vitamin E, nor 
the widely used thermostabile esteri-
fied forms of vitamin E. This is partly 
because, beyond its antioxidant effect, 
very little is known regarding the cel-
lular mechanisms through which the 
different biologically relevant forms 
of vitamin E work. Yoshida and col-
leagues (2006, this issue) demonstrate 
that a novel water-soluble vitamin E 
derivative, γ-tocopherol-N,N-dimeth-
ylglycinate hydrochloride (γ-TDMG), 
may be superior to the widely used 
α-tocopherol (α-Toc) form of vita-
min E in suppressing UVB-induced 
photo-inflammation. Moreover, they 
demonstrate that γ-TDMG inhibits the 
production of two inflammatory medi-
ators, prostaglandin E2 (PGE2) and nitric 
oxide. Finally, Yoshida et al. provide 
evidence that the ability of γ-TDMG to 
block PGE2 production may be inde-
pendent of its antioxidant properties. 
This has important implications not 
only for epidermal photo-protection 
and chemoprevention, but also for cur-
rent studies examining the chemopre-
ventive effects of vitamin E on other 
epithelial malignancies, particularly 
prostate, colon, and lung cancer.
Historical perspective
Vitamin E was first described in 1922 by 
Herbert M. Evans and Katharine Bishop. 
In their studies, an unknown factor 
that they called vitamin E was found to 
be necessary for fetal development in 
rats. Fetal development was found to 
be aborted in female rats fed a defined 
diet. However, fetal development was 
restored by the addition of plant mate-
rial, the most effective being wheat germ 
oil. Vitamin E was subsequently iso-
lated in 1936 and was given the name 
tocopherol, or “the childbirth-producing 
alcohol” (Greek tokos, childbirth; phere-
in, to bear; ol, an alcohol). In 1938, Paul 
Karrer synthesized vitamin E and dem-
onstrated its function as a lipid-soluble 
antioxidant. By the 1940s and 1950s, 
the antioxidant activity of vitamin E was 
well established, and it was recognized 
as an essential nutrient in 1968. Natural 
plant-derived vitamin E is composed of 
eight different natural derivatives (α-, 
β-, γ-, and δ-tocopherols and the related 
α-, β-, γ-, and δ-tocotrienols). Whereas 
γ-tocopherol (γ-Toc) is the most abun-
dant tocopherol found in the diet, 
